Capromorelin tartrate has been used in human clinical trials as a treatment for frailty in elderly adults.[1]
Capromorelin tartrate is an agonist of GHSR1a (ghrelin) receptors. It possesses structural homology with pyrazolinone-piperidine dipeptides.[2]
Biochem/physiol Actions
Capromorelin tartrate is a potent ghrelin receptor agonist/growth hormone secretagogue (Ki = 7 nM). In rat pituitary cells, Capromorlelin incudes growth hormone (GH) secretion with an EC50 of 3 nM. Capromorelin also increases gastric motility and has been studied recently in patients with spinal cord injuries.
British journal of pharmacology, 171(5), 1275-1286 (2014-03-29)
Some agonists of ghrelin receptors cause rapid decreases in BP. The mechanisms by which they cause hypotension and the pharmacology of the receptors are unknown. The effects of ligands of ghrelin receptors were investigated in rats in vivo, on isolated
Questions
Reviews
★★★★★ No rating value
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.